Is PT-141 (Bremelanotide) Legal in Louisiana? How to Access It Legally

HealthRX.com

PT-141 is legal only as prescription Vyleesi, not research vials

Print or save as PDF

See the public record for Bremelanotide

  • Federal status / Prescription drug, FDA-approved as Vyleesi (NDA 210557) [1][2]
  • Approval date / June 21, 2019 [2]
  • Approved use / Premenopausal women with acquired, generalized HSDD [1]
  • Not indicated for / Postmenopausal women, men, or enhancing sexual performance [1]
  • Form and dose / 1.75 mg subcutaneous autoinjector, as needed [1]
  • Boxed warning / None [1]
  • Prescription required / Yes; Vyleesi is prescription-only [1]
  • Research-use 'PT-141' / Not Vyleesi [1][4]

Bremelanotide is a prescription drug, not a research chemical

Bremelanotide is the active ingredient in Vyleesi, an FDA-approved prescription product (NDA 210557) first approved on June 21, 2019 [1][2]. It comes as a 1.75 mg prefilled autoinjector that the patient self-injects into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity [1]. The label says not to use more than one dose within 24 hours and that more than 8 doses per month is not recommended [1].

That approval is what separates bremelanotide from peptides sold for laboratory use. A vial labelled 'PT-141, for research use only' is not Vyleesi, and it is not an FDA-approved drug [1][4].

Does Louisiana add its own rules?

FDA approval is a federal status, and Vyleesi is prescription-only [1]. Louisiana's own requirements for telehealth prescribing, prescriber eligibility and dispensing are outside what this page covers.

Questions worth asking

Choose the questions you want to keep

Compounded and 'research use' PT-141

Compounded bremelanotide sits outside that approval. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before marketing [3]. Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026), and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [5][6].

Who the approved product is for

The approved indication is narrow: premenopausal women with acquired, generalized HSDD, meaning low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. Acquired means it developed in a woman who previously had no such problem; generalized means it occurs regardless of the type of stimulation, situation or partner [1].

The label states Vyleesi is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance [1]. It carries no boxed warning, and no risk evaluation and mitigation strategy appears in the label or the 2019 approval letter [1][2].

What the label says to watch for

Each dose raises blood pressure briefly. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. In an 8-day ambulatory study of 127 premenopausal women, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. The label lists uncontrolled hypertension and known cardiovascular disease as contraindications [1].

Nausea was reported by 40.0% of patients versus 1.3% on placebo; 13% used an anti-nausea medicine and 8% stopped the trials because of it [1]. The label says pre-treating with oral ondansetron 30 minutes before a dose did not reduce nausea in a phase 4 study of 228 healthy women and is not recommended [1].

Focal hyperpigmentation (darkening of skin, gums or breasts) was reported by 1% of patients using up to 8 doses a month versus none on placebo; in another study 38% developed it after daily dosing for 8 days [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, when should the 1.75 mg autoinjector be used relative to sexual activity?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is PT-141 (Bremelanotide) legal in Louisiana?
Vyleesi (bremelanotide) is FDA-approved and available by prescription for premenopausal women with acquired, generalized HSDD [1][2].
Do I need a prescription for bremelanotide?
Yes. Vyleesi is a prescription-only product dispensed as a 1.75 mg autoinjector [1].
Is compounded bremelanotide FDA-approved?
No. Compounded drugs are not FDA-approved and FDA does not review them for safety, effectiveness or quality before marketing, and products sold as 'PT-141' for research use are not Vyleesi [3][4].
Can men get a bremelanotide prescription?
The label says Vyleesi is not indicated for HSDD in men and is not indicated to enhance sexual performance [1].
Does Vyleesi carry a boxed warning or REMS?
No. The label has no boxed warning, and no risk evaluation and mitigation strategy appears in the label or the 2019 approval letter [1][2].
Show all 6 referencesHide references
PT-141 Louisiana: evidence summary chart
Image: HealthRX.com. Full PT-141 Louisiana guide and sources at healthrx.com/peptide-legal-pt-141.